Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neurofibrosarcoma × AZD 6244 × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Neurofibromatosis 1 4 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Sarcoma, Kaposi 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pain 1 Neurofibrosarcoma 1 Neurofibroma, Plexiform 1 Neoplasms 1 Lung Neoplasms 1 Liver Neoplasms 1 Carcinoma, Hepatocellular 1 Astrocytoma 1 Acquired Immunodeficiency Syndrome 1 AIDS-related Kaposi sarcoma 1

Interventions

pazopanib 2 Sirolimus 2 temsirolimus 1 selinexor 1 pexidartinib 1 pembrolizumab 1 liposomal doxorubicin 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 STA 9090 1 Proton Therapy 1 Imatinib Mesylate 1 Ifosfamide 1 HhAntag691 1 Doxorubicin 1 Docetaxel 1 AZD 6244 1 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06735820 2025-07-03

MEKMDM2

Children's National Research Institute

Phase 1/2 Not yet recruiting

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡